Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 10 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Sales are expected to decline because sales of Zokinvy are expected to be lower than initially planned and receipt of EmendoBio’s licensing revenue is expected to be postponed to the next fiscal year. Meanwhile, the loss is expected to decrease because some of the costs of manufacturing active pharmaceutical ingredients for products to be marketed after approval of HGF gene therapy products are expected to be recorded in the next fiscal year.
Impairment loss on EmendoBio’s right-of-use assets: ¥41.896 million
| Item | Details |
|---|---|
| Net Sales | ¥1,330 million → ¥1,000 million（-24.8%） |
| Operating profit | ¥-10,230 million → ¥-8,900 million |
| Ordinary income | ¥-10,240 million → ¥-9,000 million |
| Profit attributable to owners of the parent | ¥-10,250 million → ¥-9,100 million |
| Net income per share | ¥-26.35 / sen → ¥-22.77 / sen |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 10 February 2026 |
| Previous-period results | Sales: ¥874 million; operating profit: −¥5,145 million; ordinary profit: −¥5,288 million; net profit attributable to owners of the parent: −¥5,123 million; basic earnings per share: −¥14.44 |
| Reason for the revision | Sales are expected to decline because sales of Zokinvy are expected to be lower than initially planned and receipt of EmendoBio’s licensing revenue is expected to be postponed to the next fiscal year. Meanwhile, the loss is expected to decrease because some of the costs of manufacturing active pharmaceutical ingredients for products to be marketed after approval of HGF gene therapy products are expected to be recorded in the next fiscal year. |
| Details and amount of extraordinary loss | Impairment loss on EmendoBio’s right-of-use assets: ¥41.896 million |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The sales forecast was revised downward because sales of Zokinvy are expected to be lower than initially planned and receipt of EmendoBio’s licensing revenue is expected to be postponed to the next fiscal year. Meanwhile, the expected loss was reduced because some of the costs of manufacturing active pharmaceutical ingredients for HGF gene therapy products are expected to be recorded in the next fiscal year.